Director Regulatory Affairs
Kerstin joined the company with the acquisition of Sividon Diagnostics GmbH in June 2016 and assumed responsibility for Regulatory Affairs for the diagnostic kit business. As a cofounder and head of RA/QA of Sividon, she implemented and maintained an ISO 13485 certified QM system. In addition, she had the regulatory responsibility for CE marking the EndoPredict test as well as preparing a 510(k) submission to FDA for this test. She obtained a PhD in molecular biology and spent several years of academic research in renowned research institutes (EMBL in Heidelberg, Max-Planck-Institute for Developmental Biology in Tuebingen). Since 2000, she held different positions in research, development and project management in the diagnostic industry at Bayer Healthcare, Siemens and Sividon in Germany and the United States.
Country Manager Italy
Paulo da Costa
Director, International Finance
In 2002 Mr. da Costa started with KPMG where main activity was to provide recommendations to improve Bank’s investments portfolio. Late 2004 Mr. da Costa moved on to a SCA (Swedish Healthcare) where he learned the finance around healthcare products and distribution channels (both retail and B2B). Then in 2007 Mr. da Costa gathered healthcare international experience in Covidien where main goal was transfer processes to the Finance Shared Services sitting in Prague. In 2008 Mr. da Costa moved to Zurich to work with Baxter Healthcare in the Corporate Finance Department where main responsibility was to work together with the International Tax regarding the Transfer Price policies and support a lean, leveraged switch between management and statutory corporate view. In 2012, Mr. da Costa joined Myriad Genetics where he is responsible for all the international finance coordination.
Country Manager DACH (Germany, Austria and Switzerland)
Fani Kalaitsidis joined the company in January 2012 and has been appointed Country Manager DACH in July 2016. Fani has more than 16 years of healthcare experience and extensive knowledge in developing and implementing strategic plans to drive commercial growth in the life sciences, biotechnology, and diagnostic industries. Prior to joining Myriad, she held several positions at Baxter AG in the Bioscience care business. Fani is an accomplished senior executive experienced in positioning commercial companies for growth, profitability, and sustainable competitive advantage.
Fani received her Bachelor’s degree in Biology and Anthropology from Zurich University and her Executive Master’s degree of Business and Administration in General Management from St. Gallen University, Switzerland.
Gary A. King
Executive Vice President, International Operations
Country Manager France
Director, International Medical Affairs
Ralf Kronenwett joined Myriad Genetics with the acquisition of Sividon Diagnostics in June 2016 and holds the position of Director Medical Affairs and Clinical Development Kits. He received his medical degree from the University of Heidelberg. After serving as a resident physician at the University Hospital Heidelberg, Ralf Kronenwett was a research group leader at the Clinical Cooperation Unit Molecular Hematology/Oncology of the German Cancer Research Centre in Heidelberg. In 1999, he moved to the University Hospital Dusseldorf, qualified as an Assistant Professor of Molecular Medicine and focused on molecular therapeutics and diagnostics in hematology/oncology as well as biology and therapeutic use of hematopoietic stem cells. From 2006 to 2010, he held positions as senior scientist at Bayer HealthCare and Siemens Healthcare Diagnostics and was working on prognostic and predictive biomarkers in breast cancer. In 2010, Ralf Kronenwett founded together with former colleagues at Siemens the company Sividon Diagnostics GmbH as a “management buyout” and held the positions of the Chief Medical Officer and Chief Scientific Officer (CMO/CSO). He was responsible for Medical Affairs, for R&D activities and for the development of the breast cancer prognosis test EndoPredict. Ralf Kronenwett was involved in several international research projects and is a coauthor of more than 90 research journal publications.
Director of International Sales
Director Customer and Kits Operations
Frank Nowas has worked in various roles within the In-Vitro-Diagnostics and Life Science industry for 21 years. After many years in technical field service and product support functions with Beckman Coulter in Europe, he became European Project Manager for laboratory automation and led later on the Clinical Diagnostics Service Germany West. He then spent nearly five years with the German subsidiary of Waters Inc. as National Service Manager. There he managed Field Service, Customer Support and Customer training. Excellent customer service for clinical customers, pharmaceutical and chemistry industry, universities and public institutions have been the main focus of his work there. Most recently, Mr. Nowas served as Director Services International in the area of gastroenterology. His responsibilities contained optimization of customer service for direct customers and distributors throughout the world, continuous improvement to the repair center as well as creating technical support capabilities outside Europe.
Mr. Nowas received his diploma in Biomedical Engineering from the University of Applied Science in Aachen.
Senior Director International Market Access & Integrated Patient Care
He runs and oversees Myriad’s hospital and multidisciplinary ambulatory-care operations in Germany, a unique platform for partnering and for developing innovative molecular in-vitro diagnostics close to the patient.
Heinz Oehl joined Myriad in January 2012. In his previous position as Country Manager Germany and Austria, he established Myriad’s country organization and laid the foundation to offer direct-to-patient care and to partner with providers and payers within the healthcare system.
Before joining Myriad, he worked in various executive positions in the international Medical Device and Pharmaceutical industry. Previously, he drove transformation of markets in Europe, Middle East and Africa towards adoption of new life-saving organ replacement therapies in various disease entities and pathways.
Heinz Oehl carries a medical license from Free University of Berlin and was trained in Germany and the University of California in San Diego as well as at IMD executive business school in Lausanne, Switzerland.
Canadian Sales and Business Unit Manager
Managing Director Europe – Chief Commercial Officer
Jan Schlüchter joined the company in October 2015. As Managing Director Europe and Chief Commercial Officer, he oversees Country Operations across Europe. Jan has held several senior positions at Novartis over the past 12 years. Most recently, he served as Global Head of Key Account Management at Novartis’ headquarters in Basel, Switzerland. Previously, he held General Management roles in Greece and Germany.
Before Novartis, Jan was a Consultant at McKinsey and has founded two companies. He received his master’s degree in management from the University of Nuremberg, Germany and his doctor of philosophy degree in marketing from the University of Dortmund, Germany.
Country Manager UK and Ireland
David’s scientific career began in drug discovery following a PhD and Post-doctoral research in synthetic organic chemistry. After some years as a medicinal chemist, David moved into a more commercial role before joining Fisher Scientific UK Ltd as a sales representative. Following an MBA at Imperial College, London focused on healthcare, David Joined MeadWestvaco a world leading packaging manufacturer in business development progressing to European Sales Director for the Adherence Packaging and Pump Dispenser business. A second spell at Thermo Fisher Scientific saw David managing the UK, Ireland and Netherlands Clinical Diagnostics business, bringing together the innovative biomarker business with the well-established Drugs of Abuse and quality controls portfolio. David brings a good deal of experience in UK market access, having worked closely with NICE, the NIHR Diagnostic Evidence Cooperatives and NHS England. He has expertise in Health Economics, Decision Impact modelling and guideline processes.